Experiences with

Nilotinib

Hello dear, I read that a few years ago there was conducted a medical study regarding Tasigna nilotinib and hereditary ataxia. I have heard many positive experiences from people with hereditary ataxia who have used the medication. I myself have Friedreich ataxia.

Hi, Dad’s oncologist has stopped the Erlotinib as last scan in Jan showed tumour growth. Private Liquid biopsy result just back, mutation EGFR p.L747_T751de. No treatment offered by NHS, oncologist thinks will be more harmful to dad but how does he know for sure? I read some PubMed data that restarting

We thought Erlotinib was working for my dad, his tumour had reduced significantly on October scan ( started on drug Aug 23) but Jan scan showed growth, cough back and has been getting steadily worse with weight down to 7 stone ,diarrhoea and debilitating fatigue. Although Oncologist thought a standard

Hi, Dad is in 5th week of taking Erlotinib and corresponding face rash appears to be under control with prescribed cream / antibiotics. Also good to see that his cough has reduced in frequency by around 90% and no increase in fatigue. My question is- dad has actinic keratosis ( for around 25 years +

Hi All, Dad had results of liquid biopsy and EGFR positive, Oncologist has recommended Erlotinib ( NHS treatment). We understand that his diagnosis T4 N2 M0 is non curative but trying to balance quality of life and length; chemo and a standard biopsy were deemed not tolerable for my 89 yr old dad. Silly

Has anyone seen this?And what do you think? https://www.tangoherbs.com/2021/11/17/researchers-link-vascular-defects-to-progression-of-parkinsons-disease/

I always believed that TASIGNA ( generic Nilotinib) could be a game changer for treating PD. This was based on my experience taking TASIGNA off label for PD. The following positive changes I consider the most noteworthy: 1. After only five days I was sleeping through the night. 2.

Sweet syndrome induced by epidermal growth factor receptor (EGFR) inhibitors, 2022. A case of Sweet's syndrome triggered by erlotinib, an epidermal growth factor receptor inhibitor. "Epidermal growth factor receptor inhibitors are associated with multiple cutaneous toxicities, with PRIDE (papulo-pustules

Doxazosin, an alpha1-adrenoceptor antagonist, is used for the treatment of benign prostatic hyperplasia (BPH) and hypertension. Alpha-adrenoceptor antagonists also inhibit growth and induce apoptosis in malignant prostatic cells. The apoptotic activity is independent of their capacity to antagonize

Then I asked about Nilotinib. She knew of the drug but found it didn't work well enough and had side effects. Then I asked about red or infrared light therapy. She said she'd never heard of it. So I gave her a lecture on it.

Some people mentioned using the Nilotinib/Tasigna off label. Can anyone help me figure out how and where to get it cheap and safe. I like to try it. I heard it’s helpful for SCA patients. You can pm if you want to stay anonymous. Please help.

Some people mentioned using the Nilotinib/Tasigna off label. Can anyone help me figure out how and where to get it cheap and safe. I like to try it. I heard it’s helpful for SCA patients. You can pm if you want to stay anonymous. Please help.

Live-cell microscopy revealed the highly dynamic nature of the αS inclusions: for example, their rapid clearance by certain known modulators of αS toxicity, including tacrolimus (FK506), isradipine, nilotinib, nortriptyline, and trifluoperazine.

Nilotinib 300mg reverses these effects via alteration of miRNA expression, suggesting epigenomic changes that may underlie long-term disease modifying effects." Here's a link to the report: https://www.google.com/search?

Specifically, they discovered that the 300-mg dose of nilotinib reversed these effects by inactivating a protein called DDR1 that affects the ability of the blood-brain barrier to function correctly.

They announced their primary objective in Phase 2 was to determine the safety and efficacy of TASIGNA (NILOTINIB GENERIC) The Black Box warning is a show stopper, even for the Perfect Plan.

"The failure of Nilotinib to provide a clinically meaningful benefit in PD patients in two double-blind studies is discouraging, but may be explained by the fact that nilotinib does not accumulate in the brain at concentrations sufficient to inhibit c-Abl." https://movementdisorders.onlinelibrary.wiley.com

https://www.inhibikase.com/news/press-releases/detail/45/inhibikase-therapeutics-highlights-2022-pipeline-goals-and For background information on Inhibikase and IkT-148009, see this earlier thread: https://healthunlocked.com/cure-parkinsons/posts/147273266/beyond-nilotinib-a-next-generation-c-abl-inhibitor-from-inhibikase-therapeutics-ikt

This is a drug which has been mentioned here numerous times over the years, but may finally have some real results. Unfortunately this post is likely not relevant to most posters here, but for those people with an inherited form of SCA who are just beginning to see symptoms or who have no symptoms and

What happened to Nilotinib for PD. Just another drug that has fizzled out.